Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Onmel (itraconazole)
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Merz Pharma
Drug class:
CYP51A1 inhibitor
Related drugs:
‹
›
Associations
News
Trials
Filter by
Latest
8ms
KOMET-001: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1/2, N=263, Recruiting, Kura Oncology, Inc. | N=199 --> 263
8 months ago
Enrollment change
|
NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
|
NPM1 mutation • KMT2A rearrangement
|
Komzifti (ziftomenib) • Onmel (itraconazole) • Tolsura (SUBA-itraconazole)
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.